TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06511739
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05630222
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen from Caspian Taamin Company
Study: NCT05630222
Drug: Ibuprofen 400 mg plus Acetaminophen 1000 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both from Caspian Taamin Company
Study: NCT06443658
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique
Study: NCT04790812
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
Study: NCT04790812
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
Study: NCT04790812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
Study: NCT04829305
Drug: SHR2285
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2285 is a selective inhibition of human FXIa small molecule compound.
Study: NCT03285087
Drug: DEX 0.2 μg/kg/h.
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
Study: NCT05250050
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g bid
Study: NCT05250050
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g qid
Study: NCT06268327
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
Study: NCT04907149
Drug: GLPG3970 film-coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of GLPG3970.
Study: NCT04907149
Drug: [14C]GLPG3970 solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an i.v. microtracer microdose.
Study: NCT04907149
Drug: [14]GLPG3970 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose \[14C\]GLPG3970.
Study: NCT05407246
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
Study: NCT05743075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT05615987
Drug: Onabotulinumtoxina for Injection
Normalized name: Onabotulinumtoxina for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200iu/2ml in both groups
Study: NCT04697186
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
Study: NCT04367103
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prophylaxis for hypotension
Study: NCT05084560
Drug: AWZ1066S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
Study: NCT05084560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04536922
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
Study: NCT04536922
Drug: Pembrolizumab (KEYTRUDA(R))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
Study: NCT05799495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05853471
Drug: [18F]MC225
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.
Study: NCT05577364
Drug: R-CHOP Protocol
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;
Study: NCT05615194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume equivalent in infusion over 10 minutes
Study: NCT06157320
Drug: Shen-Fu
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
Study: NCT06157320
Drug: Norepinephrine (NE)，antibiotics，fluid resuscitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
Study: NCT05285124
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
Study: NCT05133713
Drug: Systemic anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy
Study: NCT05610956
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
Study: NCT06153433
Drug: Rosuvastatin Immediate-Release Tablet (IRT) 10mg
Normalized name: rosuvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin Immediate-Release Tablet (IRT) 10mg
Study: NCT06153433
Drug: Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
Normalized name: rosuvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
Study: NCT06343038
Drug: Injection, 161Tb-SibuDAB,1GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
Study: NCT06343038
Drug: Injection, 177Lu-PSMA-I&T, 1GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
Study: NCT06343038
Drug: Injection, 161Tb-SibuDAB, Dose Escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed.
Study: NCT06255067
Drug: Minocycline hydrochloride with noisome carrier
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
Study: NCT06255067
Drug: Minocycline Hydrochloride only
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
Study: NCT06606067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily
Study: NCT04848714
Drug: ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
Study: NCT06299982
Drug: 608 Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 608 160 mg at week 0 + 80 mg Q2W (5 cycles)
Study: NCT06299982
Drug: 608 Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 608 160 mg Q4W (3 cycles)
Study: NCT05528367
Drug: Nab-PTX,S-1,Tirelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w.
Study: NCT05135858
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
Study: NCT05268744
Drug: Micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take micronutrient supplement daily for 8 weeks
Study: NCT05753566
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
Study: NCT05093920
Drug: Doxorubicin-Eluting Beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: * The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.
Study: NCT05942378
Drug: HRXG-K-1939
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRXG-K-1939
Study: NCT04857437
Drug: PF-07202954 Single Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
Study: NCT04857437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT05077462
Drug: C52R1M Tab. and C52R2 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
Study: NCT05077462
Drug: AJU-C52H
Normalized name: AJUGA REPTANS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
Study: NCT04562597
Drug: Dose Response Curve Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
Study: NCT04562597
Drug: Dose Response Curve N-acetylcysteine 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
Study: NCT04562597
Drug: Dose Response Curve N-acetylcysteine 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
Study: NCT04562597
Drug: Dose Response Curve N-acetylcysteine 150 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
Study: NCT04562597
Drug: Opioid Reduction with Optimal N-acetylcysteine Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
Study: NCT04562597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
Study: NCT05768204
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
Study: NCT05908409
Drug: IDP-121
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
Study: NCT06069141
Drug: Benzathine Penicillin G
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine Penicillin G (2.4 MU intramuscularly once)
Study: NCT06069141
Drug: Doxycycline Capsule
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline (100 mg orally twice daily for 7 days)
Study: NCT05586958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04883528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
Study: NCT00041171
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05286372
Drug: AMX0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary formulation of sodium phenylbutyrate and taurursodiol
Study: NCT05497492
Drug: propofol and sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of propofol and sufentanil in combination
Study: NCT05764668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
Study: NCT05424263
Drug: Calcium Acetate Oral Solution
Normalized name: Calcium Acetate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
Study: NCT05786365
Drug: Ketalar 50 MG/ML Injectable Solution
Normalized name: Ketalar 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
Study: NCT04104919
Drug: Placebo 6 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative intrathecal injection
Study: NCT05203367
Drug: BAR502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg).
Study: NCT05203367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Study: NCT05140837
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
Study: NCT01004016
Drug: KPS-0373
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01004016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05027932
Drug: BPL-1357
Normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#BPLEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.
Study: NCT05938920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral
Study: NCT04959812
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study: NCT06120595
Drug: REBECCA-assisted intervention 1
Normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
Study: NCT05789186
Drug: CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
Study: NCT05789186
Drug: Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
Study: NCT05789186
Drug: Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without drug treatment effect
Study: NCT05330858
Drug: ESK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet or liquid
Study: NCT05593614
Drug: ATX01 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
Study: NCT05593614
Drug: ATX01 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
Study: NCT05593614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 100 mL bottle of hydrogel formulation containing no active substance
Study: NCT06196398
Drug: Standard Medical Treatment on the basis of anti-platelet therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation
Study: NCT05857449
Drug: LPM3480392
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05828472
Drug: MY008211A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: MY008211A tablets, low/moderate/high dose orally, for 7 days
Study: NCT05828472
Drug: MY008211A tablets matched placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
Study: NCT05343234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tree different placebo drugs with tree different names and scheduled will be given
Study: NCT04857645
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
Study: NCT05512702
Drug: Low-molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
Study: NCT05162001
Drug: Disulfiram 250 mg
Normalized name: disulfiram 250 MG
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram used qd during nine weeks to observe effects on body weight